Business Context and Reporting Period
Company: Immunic, Inc. (IMUX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Immunic is a late-stage biotechnology company developing novel oral therapies for neurologic and gastrointestinal diseases. The Company has no approved products and has not generated product revenue. Its primary programs include vidofludimus calcium (IMU-838) for multiple sclerosis (MS) and ulcerative colitis (UC), IMU-856 for gastrointestinal diseases, and IMU-381 for gastrointestinal diseases.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(25,579) | $(24,368) | $(77,872) | $(75,332) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.24) | $(0.55) | $(0.75) |
| Operating Expenses | $25,993 | $25,726 | $79,901 | $72,421 |
| Cash and Cash Equivalents (End of Period) | $35,132 | $59,071 | $35,132 | $59,071 |
| Accumulated Deficit | $(589,271) | $(486,224) | $(589,271) | $(486,224) |
| Net Cash Used in Operating Activities (9M) | $(66,525) | $(61,803) | $(66,525) | $(61,803) |
| Net Cash Provided by Financing Activities (9M) | $65,518 | $74,464 | $65,518 | $74,464 |
Liquidity Status: As of September 30, 2025, the Company held approximately $35.1 million in cash. Management states this is insufficient to fund operations for at least twelve months without raising additional capital, raising substantial doubt about the Company's ability to continue as a going concern.
Material Changes vs. Prior Period
- Net Loss: Net loss increased by 5% in Q3 2025 compared to Q3 2024 and by 3% for the nine-month period. The increase in the nine-month period was driven by higher operating expenses, partially offset by the absence of a $4.8 million non-cash charge related to the change in fair value of tranche rights recorded in 2024.
- Operating Expenses:
- R&D: Decreased by $1.4 million in Q3 2025 due to lower external development costs for IMU-856 and the completion of the Phase 2 CALLIPER trial in the prior year. For the nine months, R&D increased by $4.5 million, primarily due to $6.2 million in external costs for the Phase 3 ENSURE trials.
- G&A: Increased by $1.6 million in Q3 2025 and $3.0 million for the nine months, driven by higher personnel expenses and increased stock-based compensation ($1.0 million increase in Q3; $0.8 million increase in 9M).
- Capital Raises: The Company completed two significant equity offerings in the first half of 2025:
- April 2025 Offering: Raised net proceeds of approximately $4.7 million.
- May 2025 Offering: Raised net proceeds of approximately $60.7 million (gross proceeds ~$65 million) via pre-funded warrants and accompanying Series A and B warrants.
- Stock-Based Compensation: Total stock-based compensation expense increased to $3.6 million in Q3 2025 from $1.9 million in Q3 2024, and to $7.6 million for the nine months ended September 30, 2025 from $6.5 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Milestones:
- ENSURE Trials (Phase 3 MS): Enrollment completed in June 2025. Top-line data expected by the end of 2026.
- CALLIPER Trial (Phase 2 PMS): Positive data announced in April and June 2025 showing reductions in disability worsening. Management is discussing next steps with healthcare authorities.
- IMU-856: Preparing for further clinical testing contingent on financing or partnerships. Data suggests potential for weight management applications.
- Going Concern Warning: The Company explicitly states it does not have adequate liquidity to fund operations for the next 12 months. Failure to raise additional capital could force the Company to cease operations.
- Nasdaq Listing Compliance: On June 27, 2025, the Company received notice of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to a closing bid price below $1.00 for 30 consecutive days. The Company has until December 24, 2025, to regain compliance. Failure to do so may result in delisting or a transfer to the Nasdaq Capital Market, which could adversely affect stock liquidity and price.
- Unusual Items:
- Tranche Rights: The second and third tranches of the January 2024 Financing expired unexercised on October 31, 2025.
- SARs Liability: The Company recorded a $1.5 million liability for Stock Appreciation Rights (SARs) granted in July 2025, classified as a liability until shareholder approval for share settlement is obtained.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $35.1 million cash balance against projected burn rates for the Phase 3 ENSURE trials and general operations.
- Financing Plans: Assess the likelihood and terms of future capital raises given the "substantial doubt" going concern disclosure and the expiration of the January 2024 tranche rights.
- Nasdaq Status: Monitor the stock price to determine if the Company will regain compliance with the $1.00 minimum bid price requirement by December 24, 2025, or if a reverse stock split or market transfer is imminent.
- Warrant Dilution: Review the terms of the May 2025 Offering, specifically the 86.7 million pre-funded warrants and accompanying Series A/B warrants, to understand potential future dilution upon exercise.
- Clinical Data Readout: Track the timeline for the ENSURE Phase 3 top-line data (expected end of 2026) as a critical value inflection point.